stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) Revenue
Cytokinetics, Incorporated's revenue for fiscal 2025 was $88.0M, up 376.6% from $18.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $113.3M. Over the past ten years it has ranged from $7.5M (fiscal 2023) to $106.4M (fiscal 2016); the current reading is higher than 82% of that period. Cytokinetics, Incorporated ranks 90th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $88.0M | 376.56% |
| FY2024 | $18.5M | 145.34% |
| FY2023 | $7.5M | (92.04%) |
| FY2022 | $94.6M | 34.30% |
| FY2021 | $70.4M | 26.15% |
| FY2020 | $55.8M | 107.79% |
| FY2019 | $26.9M | (14.71%) |
| FY2018 | $31.5M | 135.64% |
| FY2017 | $13.4M | (87.44%) |
| FY2016 | $106.4M | 271.30% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $47.6M | 66.14% |
| Jun 2026 | $28.6M | 47.89% |
| Mar 2026 | $19.4M | 9.01% |
| Dec 2025 | $17.8M | 817.10% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. compare | $1.4B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| CORT Corcept Therapeutics Incorporated compare | $963.6M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $669.5M |
| KRYS Krystal Biotech, Inc. compare | $470.0M |
| TWST Twist Bioscience Corporation compare | $431.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $282.0M |
| CYTK Cytokinetics, Incorporated | $113.3M |
| SYRE Spyre Therapeutics, Inc. compare | $1.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on CYTK
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement